Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.26% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CTKB · Jun 30, 2024
Cytek Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-24-035264General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
13.31% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-6.19% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
107.41% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
54.56% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-18.29% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
21.45% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
15.34% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History21 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/8 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20235/8 normalizedLevel 3Sep 30, 20237/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 1.26%
- Current
- 2.26%
- Delta
- 0.99%
- Previous
- 8.82%
- Current
- 13.31%
- Delta
- 4.49%
- Previous
- 20.96%
- Current
- -6.19%
- Delta
- -27.15%
- Previous
- 122.03%
- Current
- 107.41%
- Delta
- -14.62%
- Previous
- 51.30%
- Current
- 54.56%
- Delta
- 3.26%
- Previous
- -23.93%
- Current
- -18.29%
- Delta
- 5.64%
- Previous
- 21.84%
- Current
- 21.45%
- Delta
- -0.38%
- Previous
- 12.57%
- Current
- 15.34%
- Delta
- 2.77%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CTKB Fundamental State →Transitioned To · CTKB Fundamental State →Transitioned To · CTKB CAPEX_INTENSITY_INCREASED →Transitioned To · CTKB CASH_GENERATION_INCREASED →Transitioned To · CTKB GROWTH_DECREASED →Transitioned To · CTKB INVENTORY_PRESSURE_DECREASED →Transitioned To · CTKB MARGIN_INCREASED →Transitioned To · CTKB PROFITABILITY_INCREASED →Transitioned To · CTKB R_AND_D_INTENSITY_DECREASED →Transitioned To · CTKB SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.